Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

JW Therapeutics Extends Development Collaboration with 2seventy for Autoimmune CAR-T  

publication date: Jan 2, 2024

Shanghai JW Therapeutics will collaborate with Boston’s 2seventy bio to start process development and a First-in-Human clinical trial in China of 2seventy’s chimeric antigen receptor (CAR) T-cell therapy product for autoimmune diseases. JW Therapeutics will share the cost with 2seventy. It will also have the right to negotiate an exclusive license to develop, manufacture and commercialize the product in Greater China. For its development/trial work, JW will be eligible to receive up to high double digit million dollars in milestones, plus royalty payments on sales outside of Greater China. JW is a cell therapy partnership between Wuxi Apptec and Seattle’s Juno Therapeutics. More details...

Stock Symbols: (HK: 2126) (NSDQ: TSVT)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital